Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 5
1983 6
1984 2
1986 3
1988 1
1989 5
1991 2
1992 1
1993 9
1994 14
1995 8
1996 16
1997 13
1998 16
1999 9
2000 14
2001 6
2002 11
2003 12
2004 2
2005 6
2006 8
2007 3
2008 10
2009 9
2010 5
2011 13
2012 11
2013 9
2014 9
2015 18
2016 13
2017 19
2018 11
2019 3
2020 13
2021 10
2022 13
2023 21
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

351 results

Results by year

Filters applied: . Clear all
Page 1
Reply.
Li PC, Thorat A, Jeng LB. Li PC, et al. Among authors: jeng lb. Liver Transpl. 2017 Aug;23(8):1083-1084. doi: 10.1002/lt.24792. Epub 2017 Jul 3. Liver Transpl. 2017. PMID: 28590599 No abstract available.
Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial.
Llovet JM, Kudo M, Merle P, Meyer T, Qin S, Ikeda M, Xu R, Edeline J, Ryoo BY, Ren Z, Masi G, Kwiatkowski M, Lim HY, Kim JH, Breder V, Kumada H, Cheng AL, Galle PR, Kaneko S, Wang A, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS; LEAP-002 Investigators. Llovet JM, et al. Lancet Oncol. 2023 Dec;24(12):1399-1410. doi: 10.1016/S1470-2045(23)00469-2. Lancet Oncol. 2023. PMID: 38039993 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Integrated genomic analyses of hepatocellular carcinoma.
Chang YS, Tu SJ, Chen HD, Hsu MH, Chen YC, Chao DS, Chung CC, Chou YP, Chang CM, Lee YT, Yen JC, Jeng LB, Chang JG. Chang YS, et al. Among authors: jeng lb. Hepatol Int. 2023 Feb;17(1):97-111. doi: 10.1007/s12072-022-10455-z. Epub 2022 Dec 6. Hepatol Int. 2023. PMID: 36472800
Lymphoepithelioma-like hepatocellular carcinoma.
Chen CJ, Jeng LB, Huang SF. Chen CJ, et al. Among authors: jeng lb. Chang Gung Med J. 2007 Mar-Apr;30(2):172-7. Chang Gung Med J. 2007. PMID: 17596007 Free article. Review.
351 results